

Iranian Journal of Blood & Cancer

Journal Home Page: www.ijbc.ir



PHOTO CLINIC

Hepatosplenic Mucor Balls

Mitra Khalili^{1*}, Seyyed Morteza Tabatabaie², Atbin Latifi², Maryam Kazemi Aghdam³

¹Pediatric Radiology department, Shahid Beheshti University of Medical Sciences, Tehran, Iran

ARTICLE INFO

Article History: Received: 25.06.2021 Accepted: 18.08.2021 *Corresponding author: Mitra Khalili,

Pediatric Radiology department, Shahid Beheshti University of Medical

Sciences, Tehran, Iran.
Tel/Fax: +98 21 22265488
Email: m.khalili76@yahoo.com

Please cite this article as: Khalili M, Tabatabaie SM, Latifi A, Kazemi Aghdam M. Hepatosplenic Mucor Balls. IJBC 2021; 13(3): 105-106.

A 10-year-old male with a history of B-cell acute lymphoblastic leukemia (B-ALL) in first complete remission presented with severe headache and pancytopenia 3 months after completing chemotherapy. Bone marrow aspiration and cerebrospinal fluid analysis confirmed systemic and leptomeningeal relapse. He received systemic induction with oral dexamethasone, mitoxantrone and vincristine and intrathecal chemotherapy with methotrexate, cytarabine and hydrocortisone. After 2-weeks of treatment, the patient developed neutropenic fever which persisted despite negative blood cultures. Abdominopelvic computed tomography (CT) scan showed several hypodense nodules in liver; in different sizes, the largest one in left liver lobe measuring 72×50 mm bulging the liver capsule with perihepatic inflammatory changes

(Figure 1A) and also multiple hypodense nodules in the spleen (Figure 1B). Biopsy of the liver lesion revealed aggregations of thick-walled, non-septate fungal hyphae with irregular branches in right angles (Figure 1C). A diagnosis of hepatosplenic mucormycosis was made and liposomal amphotericin was initiated. However, hepatosplenic lesions increased in number on follow up imaging and caspofungin was added. Despite receiving optimal treatment and appropriate antifungal therapies, the patient was succumbed to death due to disseminated mucormycosis.

Mucormycosis is being recognized as an increasingly important cause of morbidity and mortality in immunocompromised patients. In 2002, a consensus group of the European Organization for Research








Figure 1: A) Several hypodense nodules in the liver, in different sizes, the largest one in left liver lobe measuring 72×50 mm bulging the liver capsule with perihepatic inflammatory changes. B) Multiple hypodense nodules in the spleen. C) Aggregations of thickwalled, non-septate fungal hyphae with irregular branches in right angles in favor of mucormycosis.

²Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children's health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

³Pediatric pathology department, Shahid Beheshti University of Medical Sciences, Tehran, Iran

and Treatment of Cancer/Invasive Fungal Infections Cooperative Group (EORTC) and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (MSG) published standard definitions for invasive fungal infections for clinical and epidemiological research (1). Corticosteroid use for at least 10 days, neutropenia of ≤500 cells/µl and lymphopenia as a lymphocyte count of ≤500 cells/µl were considered as the most important risk factors for developing mucormycosis (2). In the largest population-based epidemiological study of mucormycosis among children with hematological malignancies conducted by Israeli Study Group of Childhood Leukemia, most cases of mucormycosis (92%) had been occurred in children with acute leukemias. According to that registry, the incidence of mucormycosis was 2.2% in the children with ALL and 2.1% in the children with AML (3). Most of the underlying diseases or conditions for mucormycosis have been reported to be hematological malignancies and solid organ transplantation (4). The most frequent sites of infection are rhinocerebral, followed by pulmonary, disseminated, gastrointestinal, or cutaneous; however, sporadic cases of invasive mucormycosis of the liver have been reported (4).

Hepatic mucormycosis is rare and is usually thought to be arised from gastrointestinal disease, although dissemination may occur from the other sources (5). An extensive literature review in 2019 identified 14 cases of hepatic mucormycosis without lung involvement. Three cases had splenic lesions and four had gastrointestinal lesions, suggesting the possibility of transmission to the liver and/or spleen from the gastrointestinal tracts (4). pure fungal abscesses are almost always seen in patients being treated for hematologic malignancies. The presence of fungemia along with fungal hepatic abscess is a poor prognostic factor with overall mortality approaching 80% (6). Hepatic mucormycosis is readily seen on abdominal imaging. Typical CT findings include the presence of hypodense hepatic lesions surrounding vessels without a mass effect, representing areas of liver necrosis due to fungal thrombosis. These findings are not specific but suggest the presence of an angioinvasive organism (7).

In a case report and review of the literature, all cases of splenic mucormycosis by searching PubMed publications till October 2020 has been reported. The search yielded 27 cases of splenic mucormycosis including their case. Many of the cases had underlying immunocompromised conditions, except for 6 cases. A male predominance was noted in 22 cases of splenic mucormycosis. Simultaneous involvement of stomach and spleen was seen among four immunocompromised patients. The diagnosis of splenic mucormycosis should be considered in front of splenic lesions suggesting abscess or infarction, especially among immunocompromised patients (8). Similar to our case, three children with relapsed ALL has been reported who developed fever and splenomegaly due to fungal

splenic abscess, two during the re-induction phase of chemotherapy and the third within one month after achieving a second remission (9).

Conflict of Interest: None declared.

References

- 1. Ascioglu S. Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Disease. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14.
- 2. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Clinical infectious diseases. 2008;46(12):1813-21.
- Elitzur S, Arad-Cohen N, Barg A, Litichever N, Bielorai B, Elhasid R, et al. Mucormycosis in children with haematological malignancies is a salvageable disease: A report from the Israeli Study Group of Childhood Leukemia. British journal of haematology. 2020;189(2):339-50.
- 4. Karigane D, Kikuchi T, Sakurai M, Kato J, Yamane Y, Hashida R, et al. Invasive hepatic mucormycosis: a case report and review of the literature. Journal of Infection and Chemotherapy. 2019;25(1):50-3.
- Chayakulkeeree M, Ghannoum M, Perfect J. Zygomycosis: the re-emerging fungal infection. European Journal of Clinical Microbiology and Infectious Diseases. 2006;25(4):215-29.
- Lipsett PA, Huang C-J, Lillemoe KD, Cameron JL, Pitt HA. Fungal hepatic abscesses: characterization and management. Journal of Gastrointestinal Surgery. 1997;1(1):78-84.
- 7. Hagspiel K, Kempf W, Hailemariam S, Marincek B. Mucormycosis of the liver: CT findings. AJR American journal of roentgenology. 1995;165(2):340-2.
- Hammami F, Koubaa M, Chakroun A, Smaoui F, Marrakchi C, Hentati N, et al. Survival of an immunocompetent patient from splenic and gastric mucormycosis-case report and review of the literature. Journal of Medical Mycology. 2021:101174.
- Marmon LM, Vinocur CD, Wimmer RS, Konefal SH, Weintraub WH. Fungal splenic abscesses: management in childhood leukemia. Pediatric surgery international. 1990;5(2):118-20.